KMT2D and cancer: HT55 xenograft tumors were almost completely resistant to LTX (Supplemental Figure 15, A–D), while HCT116 xenograft tumors maintained the sensitivity to LTX even at the lower dose (Supplemental Figure 15, E–H), indicating that MLL4 mutation status may be useful for patient stratification and could guide treatment plan decisions for cancer patients.